Glaukos is focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
The company was first to market with minimally invasive glaucoma surgery (MIGS), which revolutionised the treatment and management of glaucoma.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus.
Glaukos is developing micro-invasive, bio-erodible, sustained-release drug delivery platforms designed for the treatment of retinal diseases, including age-related macular degeneration and diabetic macular oedema.
Contact: www.glaukos.com
